268 related articles for article (PubMed ID: 32457989)
1. Dalbavancin for the management of osteomyelitis: a major step forward?
Almangour TA; Alhifany AA
J Antimicrob Chemother; 2020 Oct; 75(10):2717-2722. PubMed ID: 32457989
[TBL] [Abstract][Full Text] [Related]
2. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility.
Almangour TA; Perry GK; Terriff CM; Alhifany AA; Kaye KS
Diagn Microbiol Infect Dis; 2019 Mar; 93(3):213-218. PubMed ID: 30396697
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
[TBL] [Abstract][Full Text] [Related]
4. Current trends in the real-life use of dalbavancin: report of a study panel.
Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
[TBL] [Abstract][Full Text] [Related]
5. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
Gatti M; Andreoni M; Pea F; Viale P
Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of clinical evidence for dalbavancin].
Rodríguez-Pardo D
Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():33-37. PubMed ID: 28129819
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of dalbavancin against Gram-positive bacteria isolated from diabetic foot osteomyelitis.
Pantel A; Nachar O; Boudet A; Loubet P; Schuldiner S; Cellier N; Sotto A; Dunyach-Remy C; Lavigne JP
J Antimicrob Chemother; 2021 Jul; 76(8):2057-2060. PubMed ID: 33842980
[TBL] [Abstract][Full Text] [Related]
8. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections.
Petrakis V; Panagopoulos P; Papanas N
Int J Low Extrem Wounds; 2020 Sep; 19(3):236-241. PubMed ID: 32500744
[TBL] [Abstract][Full Text] [Related]
10. Dalbavancin: a new option for the treatment of gram-positive infections.
Lin SW; Carver PL; DePestel DD
Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
12. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
McSorley JC; Reyes D; Tonna I; Bateman V
Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.
Leuthner KD; Yuen A; Mao Y; Rahbar A
Expert Rev Anti Infect Ther; 2015 Feb; 13(2):149-59. PubMed ID: 25578881
[TBL] [Abstract][Full Text] [Related]
14. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
15. The role of dalbavancin in skin and soft tissue infections.
Bassetti M; Peghin M; Carnelutti A; Righi E
Curr Opin Infect Dis; 2018 Apr; 31(2):141-147. PubMed ID: 29298166
[TBL] [Abstract][Full Text] [Related]
16. Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin.
Loupa CV; Lykoudi E; Meimeti E; Moisoglou I; Voyatzoglou ED; Kalantzi S; Konsta E
Med Arch; 2020 Jun; 74(3):243-245. PubMed ID: 32801445
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
19. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
[TBL] [Abstract][Full Text] [Related]
20. The current and future off-label uses of dalbavancin: a narrative review.
De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
